Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases

Area of Science:

• Neuroscience
• Regenerative Medicine
• Cell Biology

Background:

• Stem-cell-based therapy presents a novel strategy for neurodegenerative diseases.
• Bone-marrow-derived mesenchymal stem cells (MSCs) are a promising source due to their abundance, non-tumorigenic nature, and inherent homing and chemokine secretion capabilities.
• MSCs offer an autologous source for potential therapeutic applications.

Purpose of the Study:

• To review the diverse mechanisms through which MSCs can impact neurodegenerative processes.
• To highlight the potential of a single therapeutic agent for multiple neurodegenerative conditions given shared pathological pathways.

Main Methods:

• Review of existing literature on mesenchymal stem cell mechanisms in neurodegenerative disease models.
• Analysis of cellular replacement and paracrine secretion pathways.
• Examination of genetic manipulation strategies to enhance MSC therapeutic potential.

Main Results:

• Transplanted MSCs exert therapeutic effects via cellular replacement or paracrine secretion.
• Paracrine mechanisms include the secretion of trophic factors and immunomodulation via cytokines.
• Genetic engineering can enhance MSCs to act as delivery vehicles for therapeutic proteins or to promote neural lineage reprogramming.

Conclusions:

• MSCs demonstrate multifaceted therapeutic potential for neurodegenerative diseases through various mechanisms.
• Genetic modification represents an emerging strategy to augment MSC efficacy.
• Clinical trials are underway for conditions like amyotrophic lateral sclerosis and multiple sclerosis, indicating translational progress.